Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor

• Conditions: Gastrointestinal Stromal Tumor

• Registration Number: NCT02931981
• Lead Sponsor: RenJi Hospital

Brief Summary

Our study aims to evaluate the role of Dickkopf-4 as biomarkers in the treatment of gastrointestinal stromal tumor.

Detailed Description

To identify whether Dickkopf-4 (DKK4) could be a potential biomarker for diagnosis and prognosis in patients with gastrointestinal stromal tumor (GIST). Serum was collected from 50 patients with GIST. Serological levels of DKK4 were examined by enzyme-linked immunosorbent assay (ELISA). The sensitivity and specificity was compared with modified NIH risk criteria. A 3-year follow-up was monitored to evaluate the correlation between DKK4 serum levels and relapse-free or overall survival. The expression of DKK4 in GIST tumor tissues was also evaluated using immunohistochemistry staining.

Study Timeline

• Status Verified: 2016-10
• Study Start: 2016-10
• Primary Completion: 2016-10
• Study First Submitted: 2016-10-11
• Study First Submitted QC: 2016-10-11
• Last Update Submitted: 2016-10-11
• Study First Posted: 2016-10-13
• Last Update Posted: 2016-10-13
• Study Completion: 2019-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Primary gastrointestinal stromal tumor confirmed pathologically by surgery or biopsy
• Age from 18 - 70 years
• No serious organic and mental illness;

Exclusion Criteria

• Pregnancy
• No pathologic result
• Suffering other malignancies at the same time.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall Survival	3 years

Secondary Outcome Measures

Name	Time	Method
Relapse-free Survival	3 years

Trial Locations

Locations (1)

Ethics Committee of Renji Hospital, School of Medicine,Shanghai Jiaotong University; 🇨🇳 Shanghai, China